The global blood cancer drugs market size is expected to grow from $54.83 billion in 2021 to $61.26 billion in 2022 at a compound annual growth rate (CAGR) of 11.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global blood cancer drug market size is expected to reach $89.75 billion in 2026 at a CAGR of 10.0%.
What is the Global Blood Cancer Drugs Market?
The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukemia, lymphoma, and myeloma.
Get a Sample of the global blood cancer drugs market report
https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp
What drives the Global Blood Cancer Drugs Market?
The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukemia, and 275,047 cases myeloma. Furthermore, the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drug market.
Get the full global blood cancer drugs industry report here
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Global Blood Cancer Drugs Market Segments
The global blood cancer drugs market is segmented:
By Blood Cancer Type: Leukemia, Lymphoma
By Drug: Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others
By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies
By Treatment Approach: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic
By Geography: The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Blood Cancer Drugs Global Market Report 2022 provides market size and growth forecasts for the global blood cancer drugs market, global blood cancer drugs market share, blood cancer drugs market segments and geographies, blood cancer drugs market competitive landscape including leading competitors’ revenues, profiles and market shares. The blood cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Global Blood Cancer Drugs Industry Players include Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Johnson & Johnson, Novartis, Pfizer Inc, AbbVie Inc. and Takeda Pharmaceutical Company Ltd. Based on industry trends and company analysis, the report explains a number of strategies for companies in the market.
